Zusammenfassung
Einleitung
Im Herbst 1997 richtete die Deutsche Gesellschaft für Kardiologie ein bundesweites Register ein, das den Hospital- und mittelfristigen Verlauf bei mittels perkutaner Septumablation behandelten Patienten (Pat.) mit hypertropher obstruktiver Kardiomyopathie (HOCM) erfassen sollte. Die Analyse des Hospitalverlaufs liegt inzwischen vor. Wir berichten jetzt über den mittelfristigen Verlauf (3–6 Monate) der bis September 1999 eingeschlossenen Patienten.
Ergebnisse
Rückmeldungen lagen für 222 von 242 initial erfassten Pat. vor (92%). Im Follow-up-Zeitraum (4,9±2,3 Monate) verstarben 3 weitere Pat. (Hospitalmortalität: 3 Pat. (1,2%)). Über einen zufriedenstellenden Effekt der Intervention berichteten 195 Pat. (88%). Die akut erreichte Senkung des LVOT-Gradienten (LVOTG) von 57±31 auf 25±25 mmHg in Ruhe und von 107±53 auf 49±40 mmHg unter Provokation war nach 3–6 Monaten weiter akzentuiert (auf 20±21 mmHg in Ruhe bzw. 44±40 mmHg unter Provokation, p sämtlich <0,001), was für ein zeitabhängiges lokales Remodeling im Bereich der septalen Zielregion spricht. LA-Diameter (von 46±8 auf 44±7 mm), Septumdicke (von 20±5 auf 15±5 mm) und Dyspnoe, klassifiziert nach NYHA (von 2,8±0,7 auf 1,7±0,7) nahmen ebenfalls ab (p jew. <0,001). Interventionen unter Einschluss der intra-prozeduralen Echokardiographie sowie solche mit angiographisch/ durch Druckmessung erfolgender Steuerung waren hinsichtlich der klinischen Besserung und der invasiven Resultate vergleichbar.
Schlussfolgerung
Im mittelfristigen Verlauf nach Kathetertherapie, sowohl kontrastechokardiographisch wie auch per Druckmessung/fluoroskopisch gesteuert, bestätigen sich die positiven Akutergebnisse mit einem weiteren Absinken des LVOTG. LA-Last und Septumdicke nehmen ab, die körperliche Belastbarkeit nimmt weiter zu.
Summary
Introduction
In late 1997, the German Cardiac Society set up a multicenter registry to evaluate the acute and mid-term course of all patients (pts.) treated with septal ablation for symptomatic hypertrophic obstructive cardiomyopathy (HOCM). An analysis of the acute results has already been published. We now report on the mid-term course (3–6 months) of 242 pts. registered through September 1999.
Results
Follow-up was 92% complete (n=222). During follow-up (mean: 4.9±2.3 months), an additional 3 pts. died (in-hospital mortality: 3 pts.). A satisfactory clinical effect was reported by 195 pts. (88%); 27 pts. (12%) remained in NYHA classes III and IV. Overall symptomatic improvement (NYHA class: from 2.8±0.7 to 1.7±0.7) paralleled the outflow gradient (LVOTG) reduction which was further accentuated as compared with the acute result (Doppler measurement at rest: from 57±31 to 25±25 mmHg to 20±21 mmHg; with provocation: from 107±53 to 49±40, to 44±40 mmHg, p<0.001, resp.). Left atrial (LA) diameter (from 46±8 to 44±7 mm) and septal thickness (from 20±5 to 15±5 mm; p<0.001, resp.) were also reduced. Comparing the methods for target vessel selection (i.e., with contrast echo monitoring vs pressurefluoroscopy guidance), at followup clinical improvement and hemodynamic measurements were comparable.
Conclusion
Clinical success can be achieved by septal ablation, both with the echocontrast guided and gradient-fluoroscopy guided method, in 88% of highly symptomatic HOCM pts. At mid-term follow-up, symptoms, left atrial size and septal thickness are reduced, and outflow gradients are further improved as compared to the acute result.
References
(2003) American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. Eur Heart J 24:1965–1991
Boekstegers P, Steinbigler P, Molnar A, Schwaiblmair M, Becker A, Knez A, Haberl R, Steinbeck G (2001) Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38:846–853
Braunwald E (1997) Induced septal infarction: A new strategy for hypertrophic obstructive cardiomyopathy. Circulation 95:1981
Chang SM, Lakkis NM, Franklin J, Spencer WHIII, Nagueh SF (2004) Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation 109:824–827
Cheitlin, MD, Armstrong, WF, Aurigemma GP et al (2003) ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 108:1146
Faber L, Seggewiss H, Gleichmann U (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Results with respect to intra-procedural myocardial contrast echocardiography. Circulation 98:2415–2421
Faber L, Seggewiss H, Fassbender D, Bogunovic N, Strick S, Schmidt HK, Gleichmann U (1998) Perkutane transluminale septale Myokardablation bei HOCM: Akutergebnisse bei 66 Patienten unter Berücksichtigung der Myokard-Kontrastechokardiographie. Z Kardiol 87:191–201
Faber L, Meissner A, Ziemssen P, Seggewiss H (2000) Percutaneous transluminal septal myocardial ablation for HOCM: Long-term follow-up in the first series of 25 patients. Heart 83:326–331
Faber L, Seggewiss H, Welge D, Fassbender D, Ziemssen P, Schmidt HK, Gleichmann U, Horstkotte D (2003) Vorhersage des Risikos permanenter atrioventrikulärer Überleitungsstörungen nach perkutaner Septumablation bei Patienten mit hypertropher obstruktiver Kardiomyopathie. Z Kardiol 92:39–45
Flores-Ramirez R, Lakkis NM, Middleton KJ, Killip D, Spencer WH 3rd, Nagueh SF (2001) Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 37:208–214
Gietzen FH, Leuner CJ, Obergassel L, Strunk-Mueller C, Kuhn H (2002) Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, New York Heart Association functional class III or IV, and outflow obstruction only under provocable conditions. Circulation 106:454–459
Gietzen FH, Leuner CJ, Raute-Kreinsen U, Dellmann A, Hegselmann J, Strunk-Mueller C, Kuhn H (1999) Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Eur Heart J 20:1342–1354
Heric B, Lytle BW, Miller OP (1995) Surgical management of hypertrophic obstructive cardiomyopathy. J Thor Cardiovasc Surg 110:195–208
Kimmelstiel CD, Maron BJ (2004) Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 109:452–456
Knight CJ, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Harrington D, Fassbender D, Gleichmann U, Sigwart U (1997) Non-surgical septal reduction for hypertrophic obstructive cardiomyopathy: Outcome in the first series of patients. Circulation 95:2075–2081
Kuhn H, Gietzen F, Leuner C, Gerenkamp T (1997) Induction of subaortic septal ischemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Studies to develop a new catheter-based concept of treatment. Eur Heart J 18:846–851
Kuhn H, Seggewiss H, Gietzen FH, Boekstegers P, Neuhaus L, Seipel L (2004) Catheter-based therapy for hypertrophic obstructive cardiomyopathy: First in-hospital outcome analysis of the German TASH Registry Z Kardiol 93:23–31
Kuhn H, Gietzen FH, Leuner C, Schaefers M, Schober O, Strunk-Mueller C, Obergassel L, Freick M, Gockel B, Lieder F, Raute-Kreinsen U (2000) Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol 89(Suppl 4):IV41–54
Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, Ten Cate FJ, Wigle ED et al (2003) American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42:1687–1713
Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, Danielson GK, Quinones MA, Tajik JA, Spencer WH (2001) Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38:1707–1710
Qin JX, Shiota T, Lever HM, Kapadia SR, Sitges M, Rubin DN, Bauer F, Greenberg NL, Agler DA, Drinko JK, Martin M, Tuzcu EM, Smedira NG, Lytle B, Thomas JD (2001) Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 38:1994–2000
Robbins RC, Stinson EB, Daily PO (1996) Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 111:586–594
Sahn DJ, De Maria AN, Kisslo J, Weyman A (1978) The committee on m-mode standardization of the American Society of Echocardiography. Circulation 58:1072–1078
Schulte HD, Gramsch-Zabel H, Schwartzkopff B (1995) Hypertrophische obstruktive Kardiomyopathie: Chirurgische Behandlung. Schweiz Med Wochenschr 125:1940–1949
Schulte HD, Bircks W, Lösse B (1987) Techniques and complications of transaortic subvalvular myectomy in patients with hypertrophic obstructive cardiomyopathy (HOCM), Z Kardiol 76(supp 3):145–151
Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and 3-months follow-up in 25 patients. J Am Coll Cardiol 31:252–258
Seggewiss H (2001) Current status of alcohol septal ablation for patients with hypertrophic obstructive cardiomyopathy. Curr Cardiol Rep 3:160–166
Sigwart U (1995) Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346:211–214
Spencer WH 3rd, Roberts R (2000) Alcohol septal ablation in hypertrophic obstructive cardiomyopathy: the need for a registry. Circulation 102:600–601
Spirito P, Seidman CE, Mc Kenna WJ, Maron BJ (1997) The managemant of hypertrophic cardiomyopathy. New Engl J Med 336:775–785
Wigle DE, Rakowski H, Kimball BP, Williams WG (1995) Hypertrophic cardiomyopathy: Clinical spectrum and treatment. Circulation 92:1680–1692
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Faber, L., Seggewiss, H., Gietzen, F.H. et al. Catheter-based septalablation for symptomatic hypertrophic obstructive cardiomyopathy:. ZS Kardiologie 94, 516–523 (2005). https://doi.org/10.1007/s00392-005-0256-8
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00392-005-0256-8
Schlüsselwörter
- Hypertrophe obstruktive Kardiomyopathie
- transkoronare Ablation der Septumhypertrophie
- perkutane transluminale septale Myokardablation
- Obstruktion des linksventrikulären Ausflusstrakts
- totaler AV-Block
- DDD-Schrittmacher